Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Sanofi cardiovascular products



FDA Approved Drugs in CardiologyVascular Diseases CenterWatch

8.20.2017 | Logan Miers

Praluent (alirocumab); Sanofi Aventis; For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, Approved July.

Praluent (alirocumab) ; Sanofi Aventis; For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, Approved July 2015.

Agrylin (anagrelide HCL) ; Roberts Pharmaceutical; Treatment for Thrombocythemia, Approved December 1998.

Microzide (hydrochlorothiazide) ; Watson Pharmaceuticals; Treatment for mild-to moderate hypertension, Approved January 1997.

Fenofibrate ; LifeCycle Pharma; For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007.

Cardiovascular

10.22.2017 | Jessica MacAdam

That's why we hope you find the cardiovascular information on this site to be a It removes waste such as carbon dioxide and other metabolic end products from.

As one of the main causes of death and acquired disability, cardiovascular disease is a major healthcare priority throughout the industrialised world:

Even if you felt okay before, making the changes your doctor recommends and taking your medicine may make you feel even better.

Risk factors and treatments.

Therefore, the first prevention measure consists in following an overall healthier lifestyle.

Therefore, it's important to get regular medical check-ups, no matter how healthy you think you are or how good you feel.

Sanofi

9.21.2017 | Logan Miers

Cardiovascular diseases are a group of disorders of the heart and blood vessels. “It is critical that we keep the patients in mind when we develop drugs.

See the video “The committed sisters”:

Our cardiovascular research teams are committed to developing groundbreaking treatments for genetic heart diseases that affect the heart muscle, known as cardiomyopathies. They are caused by mutations in the genes of the proteins responsible for the contraction of the heart muscle. These are inheritable diseases that affect the structure and function of the heart.

“It is critical that we keep the patients in mind when we develop drugs. It really is a huge factor in my work.” Tony Muslin MD, Vice President Cardiovascular and Fibrosis - Sanofi.

Sanofi's Unique Foothold in Diabetes and Cardiovascular

3.15.2017 | Logan Miers

Sanofi has reorganized its diabetes and cardiovascular franchise, making Apidra, Insuman, Lyxumia, and blood glucose monitoring products.

Quote data by Xignite.

Sanofi has also launched its insulin Glargine biosimilar, a biosimilar of Lantus, in Europe and Japan. Eli Lilly ( LLY ) and Boehringer Ingelheim have jointly developed Abasaglar, a biosimilar of Lantus, which is already approved in Europe. Lantus competes with drugs like Novo Nordisk’s ( NVO ) Levemir and AstraZeneca’s (AZN) Byetta.

For 4Q16, Lantus sales fell 5.1% to 1.5 billion euros, which represents nearly 75% of the company’s total diabetes sales. Lantus, a long-acting human insulin used to treat type one and type two diabetes, is sold in over 120 countries and is the largest revenue contributor for this franchise.

Subscriptions can be managed in your user profile.

FDA Approves Cholesterol Drug From Regeneron, Sanofi

4.16.2017 | Logan Miers

Federal regulators approved the first of a new class of cholesterol-lowering medicines, developed by Regeneron and Sanofi. The drug, called.

and Sanofi SA, provides a new and in some cases desperay needed option for several million high-risk heart patients who can’t get their. To Read the Full Story Subscribe Sign In Most Popular Videos Opinion Journal: CNN’s Not-So-Subtle Threat North Korea: What Comes After the ICBM Test? Trump Brings 'America First' to G-20 Summit Five Ways iOS 11 Makes iPads Actually Useful Opinion Journal: Volvo’s Electric-Car Charade Most Popular Articles So Long, Hamburger Helper: America’s Venerable Food Brands Are Struggling 2017 Ford GT: A $450,000 Road Rocket That’s Two Cars in One Everything Is Awesome! Now Is the Time to Sell City of Hartford Hires Law Firm to Consider Bankruptcy Filing In TV Ratings Game, Networks Try to Dissguys Bad Newz From Nielsen Popular on WSJ Most Popular Videos Opinion Journal: CNN’s Not-So-Subtle Threat North Korea: What Comes After the ICBM Test? Trump Brings 'America First' to G-20 Summit Five Ways iOS 11 Makes iPads Actually Useful Opinion Journal: Volvo’s Electric-Car Charade Most Popular Articles So Long, Hamburger Helper: America’s Venerable Food Brands Are Struggling 2017 Ford GT: A $450,000 Road Rocket That’s Two Cars in One Everything Is Awesome! Now Is the Time to Sell City of Hartford Hires Law Firm to Consider Bankruptcy Filing In TV Ratings Game, Networks Try to Dissguys Bad Newz From Nielsen Wall Street Journal Europe Edition U.S.